Bio-Techne Q1 sales rise 5% to $289.5 million, but GAAP EPS falls to $0.21 from $0.31
Bio-Techne reported first-quarter fiscal 2025 results for the quarter ended September 30, 2024, with net sales up 5% to $289.5 million and adjusted EPS of $0.42, versus $0.41 a year earlier. GAAP EPS fell to $0.21 from $0.31, and GAAP operating income dropped 28% to $40.0 million, which the company attributes partly to restructuring charges. The company also declared a quarterly dividend of $0.08 per share and reported shareholder votes from its annual meeting.
Key points
- Net sales rose 5% to $289.5 million; organic growth was 4%.
- GAAP EPS was $0.21 versus $0.31 a year earlier; adjusted EPS was $0.42 versus $0.41.
- GAAP operating margin was 13.8%, compared with 20.2%; adjusted operating margin was 29.0%, compared with 31.4%.
- Quarterly dividend of $0.08 per share is payable November 22, 2024, to shareholders of record on November 11, 2024.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.